Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease

Movement Disorders

Volumn 25, Issue 9, 2010, Pages 1203-1209

  Iacovelli, Elisa ^a   Gilio, Francesca ^b   Meco, Giuseppe ^a   Fattapposta, Francesco ^c   Vanacore, Nicola ^d   Brusa, Livia ^e   Giacomelli, Elena ^a   Gabriele, Maria ^a   Rubino, Alfonso ^a   Locuratolo, Nicoletta ^c   Iani, Cesare ^e   Pichiorri, Floriana ^a   Colosimo, Carlo ^a   Carbone, Antonio ^c   Palleschi, Giovanni ^c   Inghilleri, Maurizio ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SANDRO PERTINI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e S EUGENIO HOSPITAL   (Italy)

Author keywords

Bladder dysfunctions; OABq; Parkinson's disease

Indexed keywords

CABERGOLINE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NOCTURIA; OVERACTIVE BLADDER; OVERACTIVE BLADDER QUESTIONNAIRE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE; CHI SQUARE DISTRIBUTION; COMPLICATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; URINARY BLADDER, OVERACTIVE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; URINARY BLADDER, OVERACTIVE;

EID: 77955068808     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23093     Document Type: Article

References (35)

1. Singer C. Urinary dysfunction in Parkinson's disease. Clin Neurosci 1998;5:78-86.
2. Abrams P, Cardozo L. The standardization terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003;61:37-49.
3. Defreitas GA, Lemack GE, Zimmern PE, Dewey RB, Roehrborn CG, O'suilleabhain PE. Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease. Urology 2003;62:651-655.
4. Sakakibara R, Shinotoh H, Uchyama T, et al. Questionnaire based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76-85.
5. Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 2001;187:55-59.
6. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the International Prostate Symptom Score. J Neurol Neurosurg Psychiatry 2000;68:429-433. (Pubitemid 30248741)
7. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005;12:842-850. (Pubitemid 41597595)
8. Seif C, Herzog J, Van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55:118-120. (Pubitemid 38067369)
9. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-574. (Pubitemid 34876130)
10. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MD, et al. Translating overactive bladder questionnaires in 14 languages. Urology 2006;67:536-540.
11. Chapple CR. Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction-one, both or none? Nat Clin Pract Urol 2005;2:555-564.
12. Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 2006;29:206-214. (Pubitemid 44510457)
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
14. Gibb WRG, Lees AJ. The relevance of the Lewi body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;5:745-752.
15. Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998;121:451-457. (Pubitemid 28116342)
16. Junghanns S, Glöckler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004;251:19-23.
17. Pavlakis RW, Siroky MB, Goldstein I, Krane RJ. Neurologic findings in Parkinson's disease. J Urol 1983;129:80-83.
18. Galloway NTM. Urethral sphincter abnormalities in Parkinsonism. Br J Urol 1983;55:691-693.
19. Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in Parkinsonian voiding dysfunction. Lancet 1988;2:1451-1453. (Pubitemid 19016651)
20. Fitzmaurice H, Fowler CJ Rickards D. Micturition disturbance in Parkinson's disease. Br J Urol 1985;57:652-656.
21. Khan Z, Starer P, Bhola A. Urinary incontinence in female Parkinson disease patients: pitfalls of diagnosis. Urology 1989;33:486-469.
22. Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol 1988;140:117-118.
23. Sammour ZM, Gomes CM, Barbosa ER, et al. Voiding dysfunction in patients with Parkinson's disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn 2009;28:510-515.
24. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006;25:116-122.
25. Malone-Lee JGW. New data on urodynamics in the symptomatic elderly. Neurourol Urodyn 1990;9:409-410.
26. Malone-Lee JGW. Incontinence. Rev Clin Gerontol 1992;2:45-61.
27. Malone-Lee JGW, Wahedna I. Characterisation of detrusor contractile function in relation to old age. Br J Urol 1993;72:873-880. (Pubitemid 24053505)
28. Rahn DD, Roshanravan SM. Pathophysiology of urinary incontinence, voiding dysfunction, and overactive bladder. Obstet Gynecol Clin North Am 2009;36:463-474.
29. Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson's disease; changes relate to age and not disease. Age Ageing 1995;24:499-504.
30. Hattori T, Yasuda K, Kita K, Hirayama K. Voiding dysfunction in Parkinson's disease. Jpn J Psychiatry Neurol 1992;46:181-186.
31. Aranda B, Cramer P. Effects of Apomorphine and L-dopa on the Parkinsonian bladder. Neurol Urodyn 1993;12:203-209. (Pubitemid 23160774)
32. Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyper-reflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 1993;32:315-321.
33. Yoshimura N, Kuno S, Chancellor MB, De Groat WC, Seki S. Dopaminergic mechanisms underlying bladder hyperactivity in rats with unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol 2003;139: 1425-1432. (Pubitemid 37174656)
34. Hashimoto K, Oyama T, Sugiyama T, Park YC, Kurita T. Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D1 and D2 receptors in rats. J Pharmacol Sci 2003;92:143-148. (Pubitemid 36833460)
35. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 2004;23:689-696. (Pubitemid 39313943)